Ligand Pharmaceuticals
LGND
#3427
Rank
NZ$7.34 B
Marketcap
NZ$366.47
Share price
-2.27%
Change (1 day)
104.83%
Change (1 year)

P/S ratio for Ligand Pharmaceuticals (LGND)

P/S ratio as of May 2026 (TTM): 16.4

According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.31. At the end of 2025 the company had a P/S ratio of 14.0.

P/S ratio history for Ligand Pharmaceuticals from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
202514.013.06%
202412.330.17%
20239.4845.3%
20226.53-29.93%
20219.318.57%
20208.58-41.18%
201914.630.16%
201811.2-45.29%
201720.55.1%
201619.5-35.21%
201530.186.35%
201416.1-26.59%
201322.056.36%
201214.180.84%
20117.775.16%
20107.3913.73%
20096.50-31.74%
20089.52-73.03%
200735.3142.56%
200614.6192.86%
20054.97-7.18%
20045.36-29.68%
20037.6291.88%
20023.97-71.82%
200114.1

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
5.77-64.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.32-85.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
12.4-24.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
4.88-70.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
0.8112-95.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
4.26-73.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.39-85.39%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
2.32-85.85%๐Ÿ‡ฌ๐Ÿ‡ง UK
Spectrum Pharmaceuticals
SPPI
8.22-49.81%๐Ÿ‡บ๐Ÿ‡ธ USA